arrow
R

Rogerio I. Neves

Department of Cutaneous Oncology
H指数:27
被引数:3,276

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

ASO Visual Abstract: Recurrence and Survival Outcomes in Patients with Primary Merkel Cell Carcinoma with Positive, Negative or Not Performed Sentinel Lymph Node Biopsy

ASO视觉摘要:原发默克尔细胞癌患者行阳性、阴性或未行哨兵淋巴结活检的复发与生存结局

2025-12-080
PRE
Recurrence and Survival Outcomes in Patients with Primary Merkel Cell Carcinoma with Positive, Negative, or Not Performed Sentinel Lymph Node Biopsy

原发性 Merkel 细胞癌患者中,根据哨兵淋巴结活检阳性、阴性或未进行的结果分析复发与生存结局

2025-10-300
PRE
Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors
2024-02-017
OA
Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma A Randomized Clinical Trial
2022-08-0336
OA
Evidence-based clinical practice guideline: Reconstruction after skin cancer resection
2021-08-0110
OA
Evidence-Based Clinical Practice Guideline: Reconstruction after Skin Cancer Resection
2021-04-274
OA
Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma
2021-03-2217
OA
INTERIM ANALYSIS OF PHASE 2 RESULTS FOR CEMIPLIMAB IN PATIENTS WITH METASTATIC BASAL CELL CARCINOMA (MBCC) WHO PROGRESSED ON OR ARE INTOLERANT TO HEDGEHOG INHIBITORS (HHIS)
2020-12-109
OAAI
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma

黑色素瘤前哨淋巴结转移的完整解剖或观察

2017-06-08991
OAAI
Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy

序贯免疫疗法和有限疗程的BRAF抑制剂治疗后,转移性恶性黑色素瘤患者all治疗的持久完全缓解

2015-03-2527
OAAI